REMINDER: Jaguar Health to Hold Investor Webcast Tuesday, August 13th at 8:30 AM Eastern to Review Q2 Earnings and Further Review Phase 3 OnTarget Trial’s Clinically Meaningful Results in Breast and Lung Cancer Patients
Jaguar Health (NASDAQ:JAGX) has announced an upcoming investor webcast on August 13, 2024, at 8:30 AM Eastern Time. The webcast will cover Q2 2024 financial results and provide updates on the Phase 3 OnTarget trial, which showed clinically meaningful results for breast and lung cancer patients. Jaguar plans to explore approval pathways for crofelemer in these cancer types based on the trial outcomes. The company will file its Q2 2024 Earnings Report on Form 10-Q on the same day. Investors can register for the webcast through a provided link, and a replay will be available on Jaguar's website afterward.
Jaguar Health (NASDAQ:JAGX) ha annunciato un prossimo webcast per investitori il 13 agosto 2024, alle 8:30 ora orientale. Il webcast tratterà i risultati finanziari del Q2 2024 e fornirà aggiornamenti sul trial OnTarget di Fase 3, che ha mostrato risultati clinicamente significativi per i pazienti con cancro al seno e ai polmoni. Jaguar intende esplorare le vie di approvazione per il crofelemere in questi tipi di cancro in base ai risultati dello studio. La società presenterà il proprio Rapporto sugli utili del Q2 2024 su modulo 10-Q lo stesso giorno. Gli investitori possono registrarsi per il webcast tramite un link fornito, e una registrazione sarà disponibile sul sito web di Jaguar successivamente.
Jaguar Health (NASDAQ:JAGX) ha anunciado un próximo webcast para inversores el 13 de agosto de 2024, a las 8:30 AM hora del Este. El webcast cubrirá los resultados financieros del Q2 2024 y proporcionará actualizaciones sobre el trial OnTarget de Fase 3, que mostró resultados clínicamente significativos para pacientes con cáncer de mama y pulmón. Jaguar planea explorar vías de aprobación para el crofelemere en estos tipos de cáncer basándose en los resultados del ensayo. La compañía presentará su Informe de ganancias del Q2 2024 en el Formulario 10-Q el mismo día. Los inversores pueden registrarse para el webcast a través de un enlace proporcionado, y una repetición estará disponible en el sitio web de Jaguar después.
재과르 헬스(Jaguar Health, NASDAQ:JAGX)는 2024년 8월 13일 동부 표준시 기준 오전 8시 30분에 예정된 투자자 웹캐스트를 발표했습니다. 이 웹캐스트에서는 2024년 2분기 재무 결과를 다루고, 유방암 및 폐암 환자에게 의미 있는 임상 결과를 보인 3상 OnTarget 시험에 대한 업데이트를 제공합니다. 재과르는 시험 결과를 바탕으로 이러한 암 유형에 대한 크로펠레머의 승인 경로를 탐색할 계획입니다. 회사는 같은 날 2024년 2분기 수익 보고서를 10-Q 양식으로 제출할 예정입니다. 투자자들은 제공된 링크를 통해 웹캐스트에 등록할 수 있으며, 이후 재과르의 웹사이트에서 다시 시청할 수 있습니다.
Jaguar Health (NASDAQ:JAGX) a annoncé un prochain webinaire pour investisseurs le 13 août 2024 à 8h30, heure de l'Est. Le webinaire couvrira les résultats financiers du T2 2024 et fournira des mises à jour sur l'
Jaguar Health (NASDAQ:JAGX) hat ein bevorstehendes Investoren-Webinar am 13. August 2024 um 8:30 Uhr Eastern Time angekündigt. Das Webinar wird die Finanzergebnisse für das zweite Quartal 2024 und Updates zur Phase 3 OnTarget-Studie beinhalten, die klinisch signifikante Ergebnisse für Patienten mit Brust- und Lungenkrebs zeigten. Jaguar plant, Genehmigungswege für Crofelemmer bei diesen Krebsarten basierend auf den Studienergebnissen zu erkunden. Das Unternehmen wird am selben Tag seinen Gewinnbericht für das zweite Quartal 2024 im Formular 10-Q einreichen. Investoren können sich über einen bereitgestellten Link für das Webinar anmelden, und eine Aufzeichnung wird später auf der Website von Jaguar verfügbar sein.
- Phase 3 OnTarget trial showed clinically meaningful results for breast and lung cancer patients
- Company exploring approval pathway for crofelemer in breast and lung cancer
- None.
Jaguar to explore approval pathway for crofelemer in breast and lung cancer based on phase 3 results
Click here to register for investor webcast
Company plans to file its Earnings Report on August 13, 2024 on Form 10-Q for the quarter ended June 30, 2024
SAN FRANCISCO, CA / ACCESSWIRE / August 12, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today issued a reminder that the company will conduct an investor webcast on Tuesday, August 13, 2024 at 8:30 a.m. Eastern to review second-quarter 2024 financials and provide corporate updates.
Participation Instructions for Webcast
When: Tuesday, August 13, 2024 at 8:30 AM Eastern Time
Participant Registration & Access Link: Click Here
Replay Instructions for Webcast
Replay of the webcast on the investor relations section of Jaguar's website: (click here)
About the Phase 3 OnTarget Clinical Trial
The multicenter double-blind, placebo-controlled OnTarget study is a first-of-its-kind prophylactic clinical trial with a primary endpoint based on patient-reported outcomes that address the highly neglected and unmet burden of cancer therapy-related diarrhea (CTD). The study evaluated the efficacy of crofelemer, a botanical drug that modulates intestinal chloride ion channels, for its ability to prevent or substantially reduce cancer therapy-related diarrhea over the 12-week treatment period, compared to placebo. The trial involved 10 different tumor types and 24 different targeted agents, with and without multiple standard cytotoxic chemotherapies. Patients then had the opportunity to continue in a blinded 12-week extension of their phase 1 therapy. A majority of the patients chose to continue.
About Crofelemer
Crofelemer is the only oral prescription drug approved under FDA botanical guidance. It is plant-based, extracted and purified from the red bark sap of the Croton lechleri tree in the Amazon rainforest. Jaguar family company Napo Pharmaceuticals has established a sustainable harvesting program, under fair trade practices, for crofelemer to ensure a high degree of quality, ecological integrity, and support for Indigenous communities.
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.
For more information about:
Jaguar Health, visit https://jaguar.health
Napo Pharmaceuticals, visit www.napopharma.com
Napo Therapeutics, visit napotherapeutics.com
Magdalena Biosciences, visit magdalenabiosciences.com
Visit the Make Cancer Less Shitty patient advocacy program at makecancerlessshitty.com and on X, Facebook & Instagram
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that it will conduct an investor webcast on August 13, 2024, and Jaguar's expectation that an approval pathway may exist to make crofelemer available to breast and lung cancer patients for CTD. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential," or "continue," or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified, and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances, or otherwise.
Source: Jaguar Health, Inc.
Contact:
hello@jaguar.health
Jaguar-JAG
SOURCE: Jaguar Health, Inc.
View the original press release on accesswire.com
FAQ
When is Jaguar Health (JAGX) holding its Q2 2024 earnings webcast?
What will be discussed in Jaguar Health's (JAGX) upcoming investor webcast?
What are the key findings from Jaguar Health's (JAGX) Phase 3 OnTarget trial?
When will Jaguar Health (JAGX) file its Q2 2024 Earnings Report?
